Introduction {#s1}
============

In recent years, the use of next-generation sequencing (NGS) for the diagnosis of Mendelian or rare genetic disorders has entered routine clinical practice. The increasing ability to sequence entire genomes in a cost-effective manner has allowed the identification of approximately 260 novel rare genetic diseases per year ([@B6]). Focusing on the ∼1.5% of the human genome represented by coding sequences, diagnostic rates of whole-exome sequencing (WES) vary widely by inherited condition, and they range from 28 to 55% ([@B48]). By extending the focus to deep intronic and regulatory variants in non-coding regions, including structural and non-exonic variants not detectable by WES, whole-genome sequencing (WGS) increased the diagnostic rate by more than 17% ([@B39]). The high rate of undiagnosed cases is related to at least two important limitations: (i) the catalog of Mendelian phenotypes is as yet far from complete (∼300 new Mendelian phenotypes are added to the OMIM database each year ([@B11])); and (ii) although the interpretation of protein-coding regions of the genome is reliable, our understanding of non-coding variation and its functional interpretation is still limited.

Recently, different studies reported on how the application of RNA sequencing (RNA-seq) can help to shed light on the possible pathogenicity of variants of unknown significance (VUS) identified through DNA sequencing studies such as WES and WGS, as it provides direct insight into the transcriptional alterations caused by VUS and thus improves diagnostic rates ([@B16]; [@B31]). Alternative splicing (AS) is considered to be a key cellular process in ensuring functional complexity in higher eukaryotes ([@B10]). Remarkably, this process is estimated to affect more than 88% of human protein-coding genes ([@B28]). The major effector of the RNA splicing reaction is the spliceosome, a complex of hundreds of interacting proteins, and small nuclear RNAs (snRNAs) including the small nuclear ribonucleoproteins (snRNPs) U1, U2, U4, U5, and U6 ([@B57]). Each intron of the pre-mRNA is flanked by a 5\'-exon and a 3\'-exon and contains different conserved splicing signals recognized by the spliceosome: the 5\'-splice site, the branch point sequence, the 3\'-splice site, and the polypyrimidine tract located 5-40 bp upstream of the 3\' end of the intron ([@B8]) ([**Supplementary Figure 1**](#SM1){ref-type="supplementary-material"}). Since these splicing signals are not sufficient for splicing regulation, the fidelity of pre-mRNA splicing depends on interactions between *trans*-acting factors (proteins and ribonucleoproteins) and *cis*-acting elements (pre-mRNA sequences), including exonic splicing enhancer (ESE), exonic splicing silencer (ESS), intronic splicing enhancer (ISE), and intronic splicing silencer (ISS) elements ([@B4]), that exert their effects by facilitating the binding of splicing factors, which in turn positively or negatively regulate inclusion of a particular exon.

Due to its underlying complexity, AS can lead to disease in different ways. The most common alterations of the splicing process are in *cis*-acting regulatory elements that are located either in core consensus sequences (5\' splice site, 3\' splice site, and branch point) or in regulatory elements that modulate spliceosome recruitment ([@B54]). Some authors estimate that up to 62% of all disease-causing single nucleotide variants (SNVs) may affect RNA splicing ([@B40]). In terms of evolutionary conservation, about 50% of the synonymous positions in codons of conserved alternatively spliced mRNAs are under selection pressure, suggesting that conserved alternative exons and their flanking introns are strongly enriched in splicing regulatory elements ([@B4]). In this regard, it has been estimated that up to 25% of synonymous substitutions can disrupt normal splicing in the same way as non-synonymous variants or premature termination codons ([@B46]), suggesting that those regions should also be routinely examined. Different examples of Mendelian disorders have already been associated with transcriptional perturbations introduced by both synonymous and non-synonymous variants ([@B55]; [@B9]) (Supplementary Table 1). Since RNA-seq is not a part of current diagnostic genetic testing routine, these estimates seem to reflect a significant proportion of potentially diagnosable cases that remain unresolved at present. Some authors demonstrate the utility of RNA-seq to diagnose 10% of patients with mitochondrial diseases and identify candidate genes for the remaining 90% ([@B31]).

Section 1: Towards Clinical Application of RNA Sequencing {#s2}
=========================================================

During the past years, the importance of RNA-seq as a clinical diagnostic tool has increased. The possibility to analyze new types of potential pathological variants in clinical routine has led to an increase in the diagnostic rate without an excessive increment in cost or time. However, some issues of RNA-seq analysis must be resolved to ensure the diagnostic quality of the study.

RNA-seq can complement the limitations of purely genetic information by probing variations in RNA with different additional studies ([@B31]). First, the expression level of a gene or transcript outside of its physiological range can be measured. Second, cases with allele-specific expression (ASE), and therefore their association with disease predisposition, can be identified ([@B7]). Third, aberrant splicing can be recognized, which is known to be a major cause of Mendelian disorders ([@B57]; [@B54]; [@B53]).

Different studies suggest that 9 to 30% ([@B56]) of disease-causing variants have an impact on RNA expression. The measurement of gene expression is thus expected to represent an improvement of the clinical routine; for example, some authors correlate the under-expression of certain genes with loss of function (LOF). This strategy has already been used in the identification of under-expression of *RARS2* in blood, which is associated with global developmental delay, seizures, microcephaly, hypotonia, and progressive scoliosis ([@B24]).

Variable expressivity and incomplete penetrance are recurrent genetic issues in variant interpretation and may result from a combination of allelic variation, modifier genes, and/or environmental factors. A genetic condition with a reduced penetrance or high variability of symptoms may be a challenge for diagnosis. Allele-specific expression refers to the differential abundance of the allele copies and is thought to be relevant for as much as 50% of all human genes ([@B14]). This differential allele expression can favor either the mutant or the wild-type allele and hence may influence clinical penetrance in different directions ([@B8]). Assuming a recessive condition, ASE-based analysis can help to reveal mono-allelic expression (MAE). For example, variants located in conserved splice sites of exon 12 of the *SPAST* gene lead to exon skipping and cause hereditary spastic paraplegia (HSP). Degradation of aberrant transcripts by a nonsense-mediated decay (NMD) mechanism results in ASE of the *SPAST* wild-type allele ([@B40]). In contrast, asymptomatic carriers of autosomal dominant retinitis pigmentosa (adRP) are protected from the disease by ASE of the wild-type *PRPF31* allele ([@B7]). In this context, ASE-based analyses may complement DNA resequencing studies such as WES or WGS for the identification of causative and low-frequency regulatory variants ([@B32]) or disease-associated predisposition variants ([@B58]; [@B17]).

Section 2: RNA-seq, Bioinformatics Approach and New Perspectives for Knowledge of Genetic Variation {#s3}
===================================================================================================

RNA-seq data processing after NGS sequencing is mandatory for an appropriate analysis. As noted in [@B13]there is no optimal pipeline for all the different applications and scenarios in RNA-seq. However, data processing steps must be included in clinical routine in order to guarantee the quality and reproducibility of the study.

Usually RNA-seq data analysis must start with raw-data quality control. This allows obtaining a general idea of the quality of the sequencing and deciding if the quality requirements for the clinical routine are met. For this purpose different bioinformatics tools such as FastQC ([@B3]) allow to control the most important and general parameters for global evaluation, such as Phred quality score, read length distribution, GC content, k-mer over-representation, adapter content, and duplicated reads. In case of adapter removal, specific bioinformatics tools may be necessary; some of the most referenced tools are CutAdapt ([@B12]), FASTX-Toolkit ([@B26]), and Trimmomatic ([@B5]). For example, adapter presence or reduced read quality could lead to read misalignment or altered gene expression estimation and splicing event detection.

In the next step, raw-data reads are mapped against a human reference genome using a splice-aware alignment algorithm, such as STAR ([@B21]), TopHat2 ([@B30]) or HiSAT2 ([@B29]). Splice-aware aligners allow reads to partially align into splice junctions between exons ([**Figure 1**](#f1){ref-type="fig"}). In this step, there are important variables that must be evaluated and adjusted according to the type of study and phenotype. For example, the reference version of the genome ([@B27]) has an impact on the sensitivity and the specificity of variants identified. On the other hand, reference genome annotation files (such as bed or gtf) have a positive impact on mapping performance, quantification, and detection of differential expression and alternative splicing ([@B64]). To enrich reference genome annotation, some helpful databases that can be incorporated are SpliceDisease ([@B23]) and ASpedia ([@B61]). SpliceDisease links experimentally supported and manually curated splicing-mutation disease entries with genes and diseases. ASpedia provides genomic annotations extracted from DNA, RNA and proteins, transcription, and regulatory elements obtained from NGS datasets, and isoform-specific functions collected from published datasets.
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After mapping the reads to the genome, there are some technical and biological biases that can affect the sensitivity threshold. The 3\' end bias of the mapped transcripts could either indicate a technical issue of reduced performance of the number of priming positions from which reverse transcriptase can start cDNA synthesis ([@B23]) or a biological issue of RNA degradation by 5\' exonuclease ([@B61]). Assessment of this type of bias is mandatory for the acceptance or rejection of clinical routine samples, and this can be done with quality control tools such as RSeQC ([@B36]).

Prior to assessing differential expression of genes and their isoforms, mapped reads must be quantified. Tools like HTSeq ([@B2]), FeatureCounts ([@B38]), and GenomicAlignments ([@B33]) allow quantification of the number of mapped reads within a specific gene feature. Several biases like gene length ([@B25]) or GC content ([@B50]) may affect the quantification process and have a negative impact on the differential expression analysis (DEA). To reduce these biases, several methods have been described. Some methods normalize the read counts based on gene length and library size (total number of reads per replicate). As described in [@B13] the most employed methods involve the use of RPKM units (reads per kilobase of transcript and per million mapped reads) for single-end reads ([@B44]), FPKM units for paired-end reads (fragments per kilobase of transcript per million mapped reads), and TPM units (transcripts per million). Other more complex normalization strategies are based on a theoretical initial distribution or on housekeeping genes ([@B22]).

At the isoform level, other quantification methods such as Cufflinks ([@B22]) and RSEM ([@B35]) are employed. Before testing differential expression between patients, it is mandatory to control technical batch effects and possible biological bias related to biopsy site, gender, or age. Principal component analysis (PCA) or Multi-Dimensional Scaling (MDS) are useful tools for monitoring these effects. After obtaining counts for the gene or transcript level, the count data is processed with different statistical methods such as R/Bioconductor package DESeq2 ([@B41]), ([@B1]), edgeR ([@B52]), or SVA ([@B34]). These tools use batch effect adjustment or modeling to reduce this technical bias. A whole functional RNA-seq pipeline provided by ENCODE can be found in: <https://github.com/ENCODE-DCC/rna-seq-pipeline>

Allele-specific expression can be identified by correlating allele counts obtained from RNA-seq and DNA resequencing. This comparison can be processed using pileLettersAt from the R/Bioconductor package GenomicAlignments ([@B33]). Some authors indicate that the sensitivity of ASE estimation depends on different technical variables such as variant coverage, allele frequency, or the number of alternative alleles ([@B31]).

As stated in the American College of Medical Genetics guidelines ([@B49]), splice site prediction tools such as GeneSplicer ([@B47]), Human Splicing Finder ([@B18]), and MaxEntScan ([@B65]) have a higher sensitivity (∼90--100%) relative to the specificity (∼60--80%) in predicting site abnormalities. It is recommended to use different algorithms to build a single piece of evidence regarding splice site variations. Other algorithms like LeafCutter ([@B37]) rely on RNA-seq data and are able to identify variable splicing events such as: exon skipping, exon truncation, exon elongation, new exon, and complex splicing (or any other splicing event or combinations of the ones mentioned) using short-read RNA-seq data and focusing on excised introns (not relying on predefined models like other tools such as Cufflinks ([@B51])).

Section 3: Issues to Be Addressed in the Transcriptomic Approach {#s4}
================================================================

Due to the dynamic nature of the transcriptome, RNA-seq studies present an important technical complexity. Even if RNA-seq studies can be introduced into clinical routine, some conceptual problems should be solved in the coming years.

Different authors point out that one of the major difficulties in transcriptomic analysis and its application to clinical routine is tissue-specific expression ([@B16]), where genes and especially their isoforms can present a wide spectrum of splicing events and expression patterns depending on the tissue or cell type. This point is essential for a correct clinical interpretation of the variants ([@B43]), ([@B60]), but presents a problem in the initial selection of material for clinical routine. It is mandatory to assess invasiveness when obtaining the material related to the studied disease. Regarding this issue, it is documented that \"noninvasible\" material such as fibroblasts and blood present 68 and 70.6% of detectable expression of OMIM genes ([@B16]; [@B24]). This data indicates that using these tissues could help solve a broad spectrum of clinical studies using RNA-seq technology. For example, in neurological diseases, blood tissue presents a detectable expression of 76% of the genes associated with their phenotypes ([@B24]).

However, tissue-specific expression may confound RNA-seq analyses and manifests the necessity to select the optimal tissue, whose basal gene expression profile allows monitoring all genes associated with the studied phenotype. For the efficient inclusion of RNA-seq analysis into clinical routine, new biological knowledge is required and additional bioinformatics tools need to be developed. In this context, new databases based on large-scale studies have been collecting and integrating information focused on the relationships between genes, isoforms, and tissues. The database established by the GTEX consortium is one of the most important and widely referenced databases ([@B43]). As noted in [@B16], the GTEX database is used for tissue selection depending on the clinical case. This information can become the mainstay of new algorithms for the *in silico* selection of optimal tissue depending on the specific disease or phenotype studied for clinical RNA-seq analysis. Some tools using such algorithms have already been described, such as for example PAGE ().

Additionally, this type of database homogenizes the transcriptomic information from large-scale analyses and could be a valuable source of control samples for statistical contrast and the identification of relatively high frequency variants or splicing events. For this initiative to succeed, and to overcome the inter-analysis barriers, the homogenization of sequencing protocols, starting materials, coverage of analysis, patient description, and bioinformatics pipelines is essential ([@B16]). In addition, it is necessary to define the laboratory and bioinformatics parameters and tools that allow monitoring and controlling this process. For example, from a laboratory point of view, assessment of the quality and quantity of extracted RNA, or the library preparation strategy and its possible relationship with technical bias for the NGS process are some of the most important parameters to consider ([@B59]). To control this bias, different mathematical methods, such as principal component analysis (PCA) or t-Distributed Stochastic Neighbor Embedding (tSNE) based on expression have been proposed ([@B20]). Another important consideration is the definition of RNA spike-in control mixtures ([@B19]). These elements allow the evaluation of the technical and biological variability, and are essential for the identification of confounding effects, normalization processes, and quality control.

Regarding technical sensitivity and specificity of RNA-seq applied to clinical routine, the dynamic nature of transcriptomics and the complexity of some alterations, for example, splicing events or ASE deviation, multiplies the number of technical and biological variables to be considered during bioinformatics analysis ([@B15]). This complexity is reflected in the need to design mathematical methods capable of absorbing if not all, at least part of the variability present in this type of study. In this respect, there are different obstacles for bioinformatics analysis of RNA-seq data. Among them are the mapping process and the possible effect of different factors on the identification of variants, such as the presence of neighboring SNPs and small indels in the unbiased identification of ASE ([@B63]; [@B7]), junction events ([@B62]), or the isoform assembly process, where the length of reads, library preparation strategy, the initial coverage, and GC content of the transcripts could affect the accuracy of the transcript identification process ([@B42];[@B59]).

Final Remarks {#s5}
=============

The RNA-seq approach holds the promise to become an interesting clinical routine tool to increase the genetic diagnostic rate. This methodology may increase our knowledge about genetic alterations and their association to genetic diseases with the inclusion of other types of variants, such as splicing events or aberrant gene expression. This type of alterations is usually not detected by DNA resequencing analyses and may be one of the main reasons of the moderate diagnostic rate of this methodology in some diseases.

However, due to the dynamic nature of the transcriptome, RNA-seq analysis presents a high complexity, with the concomitant need to consider different technical and biological variables. The control and the effect of these possible fluctuations are currently under investigation. In this context, a deeper and more specific knowledge of the technical and bioinformatics area that varies with the analyzed disease seems necessary to guarantee a meaningful clinical outcome. In this sense, great advances are being made in bioinformatics to define, homogenize, and monitor the transcriptomic information in order to break the inter-analysis barrier, which is mandatory for clinical reproducibility. However certain issues remain outstanding that should be further defined and resolved in the coming years.
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